VIP and KPV are both discussed for their anti-inflammatory properties, but they are very different molecules that work through different pathways. Here is a clear, neutral comparison.
Quick answer
VIP (vasoactive intestinal peptide) is a naturally occurring peptide with broad anti-inflammatory and immune-regulating effects, studied in conditions like chronic inflammatory response syndrome (CIRS); it works through VPAC receptors and cAMP signaling. KPV is a small tripeptide related to a fragment of alpha-MSH, studied for anti-inflammatory and wound-healing effects, acting partly by reducing NF-kB-driven inflammation, and notably without causing skin pigmentation. They target inflammation through different mechanisms. Both are research or compounded peptides rather than mainstream FDA-approved drugs.
What is VIP?
VIP, or vasoactive intestinal peptide, is a peptide the body produces naturally. It has wide-ranging roles, including relaxing smooth muscle and modulating the immune system. In research, VIP has shown anti-inflammatory effects: it can suppress pro-inflammatory signaling and shift the immune response toward a calmer state. It has drawn particular attention in the CIRS and mold-illness community, where it is discussed as part of multi-step protocols, often administered intranasally.
VIP works largely through VPAC receptors and downstream cAMP signaling, a receptor-mediated pathway that influences immune cells and cytokine production.
What is KPV?
KPV is a tripeptide (lysine-proline-valine), corresponding to the tail end of alpha-melanocyte-stimulating hormone (alpha-MSH). It has been studied for anti-inflammatory and wound-healing properties. A defining feature is that, unlike full alpha-MSH, KPV does not stimulate melanin production, so it does not darken the skin. That makes it of interest where anti-inflammatory action is wanted without pigmentation effects.
From the FormBlends catalog
VIP (Vasoactive Intestinal Peptide)
Neuropeptide that regulates inflammation, circadian rhythm, and mucosal immunity · From $59/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about VIP (Vasoactive Intestinal Peptide) →KPV's anti-inflammatory activity is associated with reducing NF-kB-driven inflammatory signaling, a different mechanism from VIP's receptor-and-cAMP route.
VIP vs KPV: the core difference
The key distinction is mechanism and scope.
- VIP acts through VPAC receptors and cAMP signaling, with broad immune-modulating and smooth-muscle effects, and is discussed mainly in systemic inflammatory contexts like CIRS.
- KPV acts largely by dampening NF-kB-driven inflammation, with interest in localized anti-inflammatory and wound-healing uses, and without pigmentation effects.
Because they hit inflammation through different pathways, some discussions frame them as complementary rather than interchangeable.
Comparison table
| Feature | VIP | KPV |
|---|---|---|
| Type | Naturally occurring peptide | Tripeptide (alpha-MSH fragment) |
| Main mechanism | VPAC receptors, cAMP signaling | Reduces NF-kB-driven inflammation |
| Studied for | Systemic inflammation, CIRS | Anti-inflammatory, wound healing |
| Pigmentation | Not a pigment inducer | Does not induce pigment (unlike alpha-MSH) |
| Status | Research/compounded peptide | Research/compounded peptide |
A note on evidence and status
Both VIP and KPV are studied compounds rather than mainstream FDA-approved drugs for these uses, and the human evidence base is limited, especially for the specific applications people discuss online. Research peptides also carry quality and sourcing considerations because they are not regulated like approved medications. Anyone considering either should work with a qualified medical provider who can explain the evidence, monitoring, and risks rather than relying on anecdotal protocols.
Where FormBlends fits
FormBlends focuses on evidence-based health information. If your interest is in medically supervised metabolic health and weight management, FormBlends keeps plain-language guides on compounded semaglutide and a provider comparison tool.
Frequently asked questions
What is the difference between VIP and KPV? VIP is a naturally occurring peptide acting through VPAC receptors with broad immune-modulating effects; KPV is a tripeptide that reduces NF-kB-driven inflammation, without pigmentation effects.
Are VIP and KPV the same thing? No. They are different molecules with different mechanisms and different typical uses.
What is KPV used for in research? It is studied for anti-inflammatory and wound-healing properties, and is noted for not causing skin pigmentation unlike full alpha-MSH.
What is VIP studied for? Broad anti-inflammatory and immune-regulating effects, with particular discussion in CIRS and mold-illness contexts.
Can VIP and KPV be used together? Some discussions frame them as complementary because they target inflammation through different pathways, but this should be evaluated with a qualified provider.
Does KPV cause tanning like Melanotan? No. Although KPV is related to an alpha-MSH fragment, it does not stimulate melanin production, so it does not darken the skin.
Are these FDA-approved? They are generally research or compounded peptides, not mainstream FDA-approved drugs for these uses.
Are they safe? Human evidence is limited and research peptides carry sourcing and quality considerations, so any use should be medically supervised.
Sources
- National Library of Medicine, vasoactive intestinal peptide and immune regulation: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570696/
- National Library of Medicine, KPV tripeptide and anti-inflammatory activity: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683255/
Ready when you are
VIP (Vasoactive Intestinal Peptide)
Neuropeptide that regulates inflammation, circadian rhythm, and mucosal immunity · From $59/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about VIP (Vasoactive Intestinal Peptide) →